10 minutes for 72 year old Tibetan compatriots: Shanghai experts completed the first transurethral prostate blue laser vaporization in Xizang People's Hospital | Urinary calculi | Xizang

Release time:Apr 13, 2024 22:16 PM

On June 15, the establishment ceremony of the 8th Xizang Autonomous Region Medical Everest Forum Urology Sub Forum, the Shanghai Tibet Urological Plateau Summit Forum and the Xizang Urinary Calculus Minimally Invasive Technology Training Center was held in the Shigatse People's Hospital. After the meeting, Xue Wei, vice president of Renji Hospital affiliated to Shanghai Jiaotong University School of Medicine and director of the Department of Urology, led a team to complete the first transurethral blue laser vaporization of the prostate in Xizang Autonomous Region, filling the gap in this technology in Xizang Autonomous Region.

 

10 minutes for 72-year-old Tibetan compatriots

10 minutes to relieve worries for 72 year old Tibetan compatriots


10 minutes for 72 year old Tibetan compatriots: Shanghai experts completed the first transurethral prostate blue laser vaporization in Xizang People's Hospital | Urinary calculi | Xizang

The patient undergoing transurethral blue laser vaporization of the prostate is a 72 year old Tibetan male sibling. He has been experiencing progressive difficulty urinating for over 2 years and has been diagnosed with benign prostatic hyperplasia, controlled by medication. However, in the last month, his symptoms worsened, with frequent urination, urgency, incontinence and even acute urinary retention, so he was transferred to the Department of Urology of Shigatse People's Hospital.

Dr. Xuan Hanqing, a specialist in the urology department of Renji Hospital in Tibet, carefully inquired about the condition. Ultrasound examination showed that the prostate gland had enlarged, with a volume of 70mL, protruding into the bladder, and residual urine was as high as 141mL. The evaluation found that the uncle's overall condition is good, the surgical indications are clear, and Xuan Hanqing has fully communicated with the patient and their family to prepare for minimally invasive surgery for prostate hyperplasia.

Xue Wei led a team to Shigatse People's Hospital for academic exchange just as the 8th Urology Sub Forum of Xizang Autonomous Region Medical Everest Forum was held in Shigatse People's Hospital. Xuan Hanqing communicated with the urology team of Renji Hospital regarding the patient's condition and developed a thorough perioperative treatment plan for the patient. He decided to implement transurethral prostate blue laser vaporization surgery.

"Compared with traditional transurethral resection of the prostate, prostate blue laser vaporization is more thorough in removing the prostate, significantly reducing surgical time, reducing intraoperative bleeding, and achieving faster recovery. It can be used as a daytime surgery and is an ideal method for treating prostate hyperplasia." Xue Wei introduced that transurethral prostate blue laser vaporization uses laser surgical equipment independently developed in China, which has the characteristics of high tissue vaporization efficiency, small thermal damage, less bleeding, and fast postoperative recovery. When blue laser vaporization occurs, the prostate tissue instantly disintegrates. The combination of vaporization and enucleation maximizes its advantages by vaporizing along the surface of the capsule gland, maximizing the removal of proliferative glands.


10 minutes for 72 year old Tibetan compatriots: Shanghai experts completed the first transurethral prostate blue laser vaporization in Xizang People's Hospital | Urinary calculi | Xizang

Sun Jie, the person in charge and deputy chief physician of the prostate hyperplasia sub specialty in the urology department of Renji Hospital, performed surgery on the patient. During the operation, significant hyperplasia was observed in both lobes of the prostate, and there were obvious small trabecular compartments in the bladder. The entire surgery took only 10 minutes, and immediately after the surgery, the urination test was smooth and the urine color was clear.

 

Xue Wei specifically pointed out that due to the special geographical environment and climate in high-altitude areas, as well as the insufficient understanding of prostate hyperplasia among the Tibetan population, patients with prostate hyperplasia who come for treatment are generally older and often complicated with important organ diseases such as heart and lungs or functional deficiencies, which puts higher requirements on the efficacy and safety of surgery. It is hoped that with the technical support of the Department of Urology of Renji Hospital, transurethral blue laser vaporization of the prostate can be vigorously developed in Xizang to protect the prostate health of elderly men in Tibet.

Under the leadership of the Department of Urology of Renji Hospital, Xigaze People's Hospital established the Tibet Urinary Calculi Minimally Invasive Technology Training Center, which is currently the first minimally invasive urinary calculi training center in the Tibet Autonomous Region. At the same time, the establishment of the training center is also another important measure for medical assistance to Tibet since Renji Hospital and Xigaze people's Hospital signed the "hospital package" counterpart support cooperation agreement in August 2017. In the future, it will strengthen the training of special technical personnel, improve the level of clinical diagnosis and treatment services of urology in Xigaze people's Hospital, and create a medical team that can not be taken away.


10 minutes for 72 year old Tibetan compatriots: Shanghai experts completed the first transurethral prostate blue laser vaporization in Xizang People's Hospital | Urinary calculi | Xizang

Building an unstoppable medical team

Led by the Department of Urology of Renji Hospital, the Shigatse People's Hospital established the Xizang Urinary Calculus Minimally Invasive Technology Training Center, which is currently the first minimally invasive technology training center for urinary calculi in the Xizang Autonomous Region. At the same time, the establishment of the training center is another important measure of medical assistance to Tibet since the signing of the "hospital package department" cooperation agreement between Renji Hospital and Shigatse People's Hospital in August 2017. In the future, it will strengthen the cultivation of specialized technical talents, improve the clinical diagnosis and treatment service level of the urology department of Shigatse People's Hospital, and build a medical team that cannot be taken away.

The establishment ceremony was presided over by Ge Wang, Vice President of Shigatse People's Hospital, and Xue Wei and Ge Wang jointly unveiled the plaque for the training center.

Why is "Cancer King" immunotherapy ineffective? Fudan Cancer Hospital Reveals New Mechanisms of Immunosuppressive Environment for pancreatic cancer CRIP1 | Tumor | pancreatic cancer
Why is "Cancer King" immunotherapy ineffective? Fudan Cancer Hospital Reveals New Mechanisms of Immunosuppressive Environment for pancreatic cancer CRIP1 | Tumor | pancreatic cancer

Immunotherapy has been proven to achieve significant therapeutic effects in various solid tumors. However, for pancreatic cancer, known as the "king of cancer", immunotherapy has been ineffective. On August 4, Professor Yu Xianjun, Dean of the Cancer Hospital Affiliated to Fudan University, and Shi Si, Associate Professor of Pancreatic Surgery released a research achievement, which first found the key role of cysteine rich protein 1 in shaping the immunosuppressive microenvironment of pancreatic cancer, filled the gap in the research field of immunosuppressive microenvironment of pancreatic cancer, and provided a theoretical basis for precise immunotherapy of pancreatic cancer patients. Ductal adenocarcinoma of the pancreas is the main type of pancreatic cancer, accounting for about 90% of all pancreatic cancer. Due to its high malignancy and poor treatment effectiveness, pancreatic ductal adenocarcinoma has always been one of the most malignant tumors. In recent years, the level of surgical techniques and comprehensive treatment has been achieved

A 14-year-old girl suffers from a rare eye disease and receives support from a public welfare fund. Symptoms of "I haven't looked in the mirror for a long time" | Patient | Public welfare
A 14-year-old girl suffers from a rare eye disease and receives support from a public welfare fund. Symptoms of "I haven't looked in the mirror for a long time" | Patient | Public welfare

A 14-year-old girl has been experiencing symptoms such as protruding pupils, incomplete eye closure, corneal injury, restricted eye movement, and overall fatigue for several years. The physical discomfort and facial abnormalities caused by eye diseases have made her increasingly reticent, and her temperament is vastly different from before. At the Ophthalmology Department of the Ninth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, the pupil has been diagnosed with a rare thyroid ophthalmopathy combined with myasthenia gravis, which requires prompt treatment. However, considering the young age of the pupil, conventional hormone and radiation therapy cannot be used. Therefore, Zhou Huifang, Deputy Director of Ophthalmology and thyroid ophthalmology expert, has developed a targeted drug combined with surgical treatment plan for it, and targeted drug treatment will be performed first. Three months ago, I was hospitalized for one week with mydriasis and received intravenous targeted drug treatment. Afterwards, I went home for observation and followed up on time

The municipal eye disease prevention and treatment center launched the dry eye diagnosis and treatment studio, and the incidence rate of dry eye in China is about 21% to 30% of the meibomian gland | dry eye | eye disease
The municipal eye disease prevention and treatment center launched the dry eye diagnosis and treatment studio, and the incidence rate of dry eye in China is about 21% to 30% of the meibomian gland | dry eye | eye disease

According to the Statistics of Chinese Dry Eye Expert Consensus, the incidence rate of dry eye in China is about 21%~30%, and it is estimated that there are at least 300 million patients nationwide. The Dry Eye Diagnosis and Treatment Studio of Shanghai Eye Disease Prevention and Treatment Center was officially launched today. In the future, the studio will continuously improve the dry eye diagnosis and treatment standards, and form standardized diagnosis and treatment concepts and service models. Suitable technologies will be promoted to the community, allowing residents to enjoy convenient dry eye diagnosis and treatment services at their doorstep. Executive Dean and Party Secretary Gao Wei stated that this is also one of the livelihood service measures recently launched by the hospital around high-quality development and meeting the needs of the people. It is reported that dry eye syndrome is a chronic ocular surface disease caused by multiple factors. The instability of the tear film or imbalance of the ocular surface microenvironment caused by abnormal quality, quantity, and dynamics of tears can be accompanied by ocular surface inflammatory reactions, tissue damage, and nerve abnormalities, resulting in various discomforts in the eyes

The Ninth Hospital has taken the lead in formulating the world's first consensus on core indicators for clinical evaluation of dental implants, which has been officially published in clinical practice
The Ninth Hospital has taken the lead in formulating the world's first consensus on core indicators for clinical evaluation of dental implants, which has been officially published in clinical practice

The International Dental Implant Consensus Report, jointly written by the Ninth People's Hospital affiliated with Shanghai Jiao Tong University School of Medicine and renowned universities in the field of dentistry such as Harvard University, University of Zurich, University of Gothenburg, Columbia University, and University of Frankfurt, has recently been jointly published in top journals in the field of dentistry, including Clinical Periodontology and Clinical Dental Implant Research. This consensus has for the first time established an internationally unified core set of indicators for evaluating the clinical effectiveness of dental implants, covering the five key areas of the field of dental implants. It is of milestone significance for carrying out standardized clinical diagnosis, treatment, and research on dental implants. The core evaluation indicators determined by this consensus will become an important benchmark for scholars in the field of dental implants worldwide to conduct high-quality research. The consensus is composed of 8 top international experts in the field of oral implantation

Recently, autologous hematopoietic stem cell therapy was completed in Shanghai, and British girls born in the 1990s have suffered from multiple relapses of blood diseases, including stem cells, peripheral blood, and diseases
Recently, autologous hematopoietic stem cell therapy was completed in Shanghai, and British girls born in the 1990s have suffered from multiple relapses of blood diseases, including stem cells, peripheral blood, and diseases

Recently, Catherine, a British girl born in the 1990s, received autologous peripheral blood hematopoietic stem cell transfusion at the Cancer Center of Shanghai Jiahui International Hospital, and was successfully discharged from the warehouse. She is now on her way back to China after being discharged from the hospital. She is also the first patient at Shanghai Jiahui International Hospital to complete relevant treatments. In 2019, Catherine was diagnosed with Hodgkin's lymphoma in the UK, and after treatment, the disease completely improved. During her work and life in China in 2021, she went to seek medical attention due to multiple enlarged lymph nodes. Pathological biopsy confirmed a recurrence of Hodgkin's lymphoma, and through combined targeted drug treatment, her condition was temporarily under control. Last year in the second half of the year, when the disease recurred, the girl began to use immunotherapy combined with targeted drugs for treatment. Expert evaluation suggests that for young patients with hematological tumors, the risk of recurrence is high and treatment difficulty is increasing in the future. Autologous hematopoietic stem cell therapy is recommended